A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Stopped Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC

Conditions

• Non-small Cell Lung Cancer Stage III

Interventions

• DRUG: Paclitaxel
• DRUG: Placebo for Veliparib
• DRUG: Carboplatin
• DRUG: Veliparib
• RADIATION: Radiotherapy

Sponsor

AbbVie